The treatment of hidradenitis suppurativa with the glucagon‐like peptide‐1 agonist liraglutide

Abstract

Hidradenitis suppurativa (HS) is a cutaneous disease associated with systemic inflammation, obesity and metabolic syndrome. Effective treatment options are limited. The antidiabetic agents, incretins, have been used successfully to treat psoriasis – a disease also associated with metabolic syndrome. We report the use of liraglutide, a glucagon‐like peptide‐1 agonist, in a patient with HS, leading to subsequent weight loss and improvement in disease control. To our knowledge, this is the first report of liraglutide used in the treatment of HS.